Sexual Dimorphism in Cystinuria- The Mitochondria Link
Unravelling the role of mitochondrial Slc3a1 in regulating mitochondrial functions and sexual dimorphism in cystinuria
CHINA, March 28, 2025 / EINPresswire.com / -- Cystinuria is the most common inheritable cause of kidney stone disease, characterized by impaired reabsorption of cystine and dibasic amino acids in the renal proximal tubules. It exhibits a sex-dependent response, with males experiencing an earlier onset of stone formation and a high number of large-sized stones; however, the cellular origin and mechanisms underlying this sexual dimorphism remains elusive. Recent studies have shown that mitochondrial dysfunction plays a key role in the pathogenesis of renal diseases. It has also been evidenced that there are significant sex-related differences in mitochondrial morphology, function, and homeostasis, as well as variations in response to acute kidney injury and progression of chronic kidney disease.
In a recent study published in the Genes & Diseases journal, researchers from Shanghai Jiao Tong University School of Medicine, East China Normal University, Shanghai University of Traditional Chinese Medicine, Tongji University, and Fudan University unravel the critical role of mitochondrial Slc3a1 in regulating mitochondrial functions and sexual dimorphism in cystinuria.
To investigate the mechanisms underlying sexual dimorphism in cystinuria, the authors examined stone formation and kidney injury in Slc3a1 knock-out (KO) mice, Slc3a1, Slc7a13 double KO mice, and orchiectomized Slc3a1 KO mice. The Slc3a1 KO female mice had smaller and less severe bladder stones, concomitant with a lower expression of fibrotic and immune markers than the Slc3a1 KO male mice, showing that cystinuria was more pronounced in males than in females. This severity could not be rescued even upon double KO of Slc3a1 and Slc7a13 or orchidectomy, which establishes that the male susceptibility to cystinuria is dependent on Slc3a1 and independent of Slc7a13.
Mitochondrial functions were found to be impaired in the renal tubule cells of Slc3a1 KO male kidneys, resulting in exacerbated damage caused by the accumulating debris and formation of cystine crystal-containing stones; whereas, high SLC3A1 protein levels were associated with enhanced mitochondrial functions in the kidney. By integrating unbiased bulk RNA sequencing, single-cell RNA sequencing, and molecular experiments, the authors showed that i) the differential mitochondrial functions between SLC3A1high male kidneys and SLC3A1low female kidneys primarily arise in the proximal tubule cells; and ii) Slc3a1 enhances mitochondrial functions by increasing mitochondrial NAD+ uptake in the proximal tubules.
In conclusion, this study highlights the critical role of mitochondrial functions in regulating sexual dimorphism in cystinuria. It also suggests that restoring mitochondria in renal tubules of male cystinuria patients may improve mitochondrial function, leading to reduced cell death and attenuation of fibro-inflammation in the renal tubules.
Reference
Title of the original paper - Mitochondrial SLC3A1 regulates sexual dimorphism in cystinuria.
Journal - Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI - https://doi.org/10.1016/j.gendis.2024.101472
Funding Information:
Science and Technology Commission of Shanghai Municipality of China (No. 23Y21900102; 23ZR1467900 to Q.W.)
Shanghai Rising-Star Program (No. 22QA1405900)
The National Key R&D Program of China (No. 2022YFC2505400, 2022YFC3400203)
The National Natural Science Foundation of China (No. 82100773; 82101486, 82371426)
The Natural Science Foundation of Chongqing, China (No. CSTB2022NSCQ-MSX1621)
The Ningxia Hui Autonomous Region Key Research and Development Project (China) (No. 2022BFH02012)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
# # # # # #
https://www.sciencedirect.com/journal/genes-and-diseases).
https://www.editorialmanager.com/gendis/default.aspx).
CN: 50-1221/R
Genes & Diseases Editorial Office
Genes & Diseases
+86 23 6571 4691
X
LinkedIn
Instagram
YouTube
Other
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Sly Stone, 82, dies after 'prolonged battle' with COPD: Signs, symptoms and risk factors
Sly Stone, the funk icon and frontman of the group Sly and the Family Stone, has died. The 82-year-old musician's family confirmed the death of their "beloved dad" following a "prolonged battle" with COPD (chronic obstructive pulmonary disease) and undisclosed "underlying health issues." "Sly passed away peacefully, surrounded by his three children, his closest friend and his extended family,' the family's June 9 statement read. 'While we mourn his absence, we take solace in knowing that his extraordinary musical legacy will continue to resonate and inspire for generations to come.' This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. Stone, born Sylvester Stewart, helped pioneer a new sound of funk, pop and rock in the '60s, '70s' and '80s with hits like "Dance to the Music," "Sing a Simple Song" and "Everyday People." Stone and his band were inducted into the Rock & Roll Hall of Fame in 1993 and received a Lifetime Achievement Grammy Award in 2006. "His iconic songs have left an indelible mark on the world, and his influence remains undeniable." the family's statement continued. "In a testament to his enduring creative spirit, Sly recently completed the screenplay for his life story, a project we are eager to share with the world in due course, which follows a memoir published in 2024." Stone addressed his health issues in a 2023 interview with The Guardian. 'I have trouble with my lungs, trouble with my voice, trouble with my hearing and trouble with the rest of my body, too,' he said. Stone later added that his ailments, "haven't stopped me from hearing music, but they have stopped me from making it." What is COPD is it something you should worry about when it comes to your own health? Read on to learn more about COPD. COPD is a progressive lung disease that causes airways to become swollen and blocked. It's an umbrella term used to describe various lung conditions, including chronic bronchitis and emphysema, according to COPD Canada. In chronic bronchitis, the airways in your lungs become inflamed and narrowed. This means eventually, you will develop more mucus, leading to a persistent cough and difficulty breathing. For emphysema, the disease develops over time and involves the gradual damage of tiny air sacs in your lungs called alveoli. The damage eventually causes these air sacs to rupture, reducing the surface area that lets oxygen move through the bloodstream. The most common symptoms of COPD are difficulty breathing, chronic cough (sometimes with mucus) and feeling tired, according to the World Health Organization (WHO). The Canadian Lung Association added a person with COPD might also present some of the following symptoms: Feeling short of breath Lung infections (like the flu or pneumonia) that may last longer than they would in others Wheezing Losing weight without trying These symptoms can get worse quickly and may be called flare-ups. "These usually last for a few days and often require additional medicine," WHO stated. COPD develops over time, often as a result of a combination of risk factors, according to the WHO. These may include: Smoking or being exposed to second-hand smoke Exposure to dusts, fumes or chemicals in the workplace Indoor air pollution from sources like burning fuel for heat or coal to cook Asthma in childhood Early life events, including poor growth in utero, prematurity or frequent respiratory infections A rare genetic condition called alpha-1 antitrypsin deficiency The Canadian Lung Association indicated adults over age 40 who smoke or previously smoked may be at risk of COPD. "It is important to speak to a healthcare provider if you are at risk of COPD, even if you don't have symptoms or have only mild symptoms," the organization stated. "COPD is a progressive disease, meaning it gets worse over time." COPD is severely underdiagnosed, according to the health charity. That's because people living with the disease may not show any symptoms, or they link their symptoms to factors like age, a common respiratory infection or a "smoker's cough." Moreover, some people who have stopped smoking may believe they can no longer develop COPD. Historically, COPD was associated with older men who had a history of smoking. While the number of men and women who die of COPD in Canada each year is roughly equal, recent research has indicated COPD is likely underdiagnosed in women. The Canadian Lung Association shared women might also experience more severe symptoms and have earlier disease onset. Finally, over the past two decades, there has been a rising number of COPD hospitalizations for both women in the 40 to 64 age group as well as those older than 65. That's in addition to a decreasing number of hospitalizations in men. View this post on Instagram A post shared by Lung Health Foundation (@lunghealthfoundation) In Canada, one in four people will be diagnosed with COPD. There are more than two million Canadians impacted by the disease, and a further one million likely living with the condition unknowingly. COPD is also the second-leading cause of hospitalization in Canada, behind only childbirth. Globally, the WHO has indicated COPD is the third-leading cause of death, causing more than three million deaths in 2019 alone. That year, there were more than 212 million prevalent cases of COPD reported worldwide. There is no cure for COPD. Still, there are ways to improve the condition and possibly slow its progression. Since the majority of COPD cases are related to using cigarettes, it's best to never smoke — or stop smoking now. Moreover, you should speak to your supervisor about protection if you work around occupational exposure to chemical fumes, dusts or anything other elements that may increase your risk for COPD.
Associated Press
04-06-2025
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
04-06-2025
- Associated Press
Young Philanthropist Jahkil Naeem Jackson Releases His Third Book: 'Built Different'
Two-Time Best Selling Author, Jahkil Naeem Jackson, Releases His Third Empowering Book, 'Built Different' — A Must-Read Blueprint for Today's Youth 'I want readers to know that being different is a strength — your path won't look like everyone else's, and that's exactly the point'— Jahkil Jackson CHICAGO, CA, UNITED STATES, June 4, 2025 / / -- Following the success of his previous books 'I Am' and 'Don't Wait to Be Great', 17-year-old CNN Hero, student-athlete, motivational speaker, and non-profit founder Jahkil Naeem Jackson returns with his most powerful work yet — 'Built Different.' At just 17, Jahkil has already become a nationally recognized change-maker, and his latest book delivers raw honesty, inspiration, and practical advice for teenagers navigating the pressures of growing up in today's fast-paced, image-driven world. 'Built Different' is more than just a book — it's a real-talk guide for teens who are striving to be their best selves while battling the pressure to be perfect. Equal parts motivational blueprint and uplifting pep talk, the book creates a safe space where young people can feel seen, heard, and empowered to lead with authenticity. Jahkil opens up about his own life experiences — balancing academics, athletics, entrepreneurship, leadership, and mental wellness — offering readers mindset tools and real-life strategies they can actually apply to their own journeys. 'I want readers to know that being different is a strength — your path won't look like everyone else's, and that's exactly the point,' says Jahkil. 'This book is about embracing who you are, even when the world tries to tell you to be something else.' With a strong focus on mental health awareness, self-leadership, and resilience, 'Built Different' speaks directly to the challenges today's teens face — from anxiety and burnout to the pressure of social media and expectations from others. Jahkil's voice is relatable, compassionate, and refreshingly authentic, making 'Built Different' a must-read for youth, parents, educators, and anyone invested in helping the next generation succeed. Jahkil's journey has already inspired thousands. As the founder of Project I Am — a nonprofit organization dedicated to supporting the homeless — he has proven that age is no barrier to impact. With 'Built Different', he continues to show that purpose, courage, and leadership can start at any age. 'Built Different' is now available online at Amazon and Barnes & Noble. Claudia Greene Mayhem Entertainment Public Relations email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
